Totals exclude respondents who indicted this was not applicable to their role | Yes | No | ||
---|---|---|---|---|
 | n | % | n | % |
1. Is there a system in place for ordering and distribution of the BNF, the NPF for Community Practitioners and the Drug Tariff? (n = 27) | 27 | 100 | 0 | 0 |
2. Do you monitor NMP legislation and ensure that policies are updated in line with the revised legislation? (n = 26) | 25 | 96.2 | 1 | 3.8 |
3. Do mechanisms exist to ensure all NMPs are kept informed of relevant clinical information, e.g. Patient Safety Notices, Drug Alerts and Hazard Warnings? (n = 27) | 25 | 92.6 | 2 | 7.4 |
4. Is there an up-to-date NMP policy in place? (n = 27) | 24 | 88.8 | 3 | 11.2 |
5. Is there is a mechanism in place to ensure the selection of suitable candidates for NMP training? (n = 27) | 24 | 88.8 | 3 | 11.2 |
6. Is there a system in place for the acquisition and retention of specimen signatures to identify prescribers? (n = 27) | 23 | 85.2 | 4 | 14.8 |
7. Are NMPs receiving appropriate support or supervision in their prescribing role (e.g. local clinical supervision groups/learning sets or peer-support groups)? (n = 27) | 22 | 81.5 | 5 | 18.5 |
8. Do NMPs have an agreed scope of practice or equivalent and is a copy of this retained by the organisation? (n = 26) | 21 | 80.8 | 5 | 19.2 |
9. Do NMPs identify and fulfil continuing professional development needs relevant to their clinical work? (n = 25) | 20 | 80.0 | 5 | 20.0 |
10. Are systems for monitoring prescribing (e.g. PACT data) in place in all sectors of practice? (n = 27) | 18 | 66.7 | 9 | 33.3 |
11. Are NMPs involved in the development of local formularies and guidelines e.g. drug and therapeutic committee? (n = 26) | 17 | 65.4 | 9 | 34.6 |
12. Do NMPs participate in regular clinical audit and reviews of their clinical services? (n = 23) | 15 | 65.2 | 8 | 34.8 |
13. Do practitioners in all areas of practice have access to monitoring data? (n = 27) | 14 | 51.9 | 13 | 41.8 |